Parkinson's Movement
12,407 members11,024 posts

Vaccine Against Key Parkinson's Target

study results support the continued development of a vaccine against the key Parkinson's protein alpha-synuclein. Researchers hope this therapy may slow or stop disease progression

Many (42 percent) of antibody responders from the first trial did not need to increase their dopamine medication over the study observation period (an average of three years). Future studies will be designed to assess efficacy.

7 Replies

This is great news! I hope something will get to market for some of us hoping for a reversal before it's too late!

1 like

If you are interested in reversing pd then why not use something that has been proven in a rat model? Just take uridine ( you can get it from amazon or swanson) and DHA capsules. It takes about a month to work. I think it has helped me a lot and I have been taking it for only 10 days. Hopefully in a few more weeks I will see complete reversal. I take the uridine and dha 3 times a day with my meds.


Any comments from your PD Dr on this? I ask this as I am very close to going on Tasigna. My PD Dr doesn't want to be involved if I go on Tasigna. He says more study is needed. Doubt we'll see Tasigna FDA approval for PD before 5-7 years. I can't wait that long. Diagnosed with PD 2010.

1 like

Nilotnib has many potential side effects, one of which is death. I would be scared to take it. Also it only works in some people. It is high risk to reward.


Yes there is a certain amount of risk. You must decide if that is acceptable. Not to minimize what you are saying, as there is risk every time you get into a car. That's why Novartis lists several testing requirements prior and during usage. If something shows up you are informed and you can modify your approach.


Strange, but my Dr supports DBS over Tasigna taken at less than 20% of the dose that a leukemia patient would take. (150 mg vs 800 mg)


Here is a partial list of nutrients/minerals/herbs which have been shown to attenuate alpha synuclein:

Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.

Theaflavins stimulate autophagic degradation of a-synuclein in neuronal cells

Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.

Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model

Zinc protects SK-N-SH cells from methamphetamine-induced alpha-synuclein expression.

Selenomethionine prevents degeneration induced by overexpression of wild-type human alpha-synuclein during differentiation of neuroblastoma cells.

Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein.

Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3

The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils.

NOTE: The flavonoid baicalin is converted into baicalein in the body, brain and central nervous system. Baicalin is a component of the herb Scutillaria Baicalensis

Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.

Pyrroloquinoline quinone (PQQ) prevents fibril formation of α-synuclein


You may also like...